GVQW3
gene geneOn this page
Summary
GVQW3 (GVQW motif containing 3, HGNC:51239) is a protein-coding gene on chromosome 11q13.5, encoding Protein GVQW3 (Q3ZCU0).
At a glance
- Clinical variants (ClinVar): 1 total
- MANE Select transcript:
NM_001347885
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:51239 |
| Approved symbol | GVQW3 |
| Name | GVQW motif containing 3 |
| Location | 11q13.5 |
| Locus type | gene with protein product |
| Status | Approved |
| Ensembl gene | ENSG00000179240 |
| Ensembl biotype | protein_coding |
| Entrez | 100506127 |
Gene structure
Transcript identifiers
Ensembl transcripts: 11 — 6 protein_coding, 3 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay
ENST00000321844, ENST00000529331, ENST00000530460, ENST00000531207, ENST00000531785, ENST00000534586, ENST00000607673, ENST00000662483, ENST00000663165, ENST00000667240, ENST00000673806
RefSeq mRNA: 4 — MANE Select: NM_001347885
NM_001282456, NM_001305225, NM_001347884, NM_001347885
CCDS: CCDS73348, CCDS81599, CCDS86231, CCDS91541
Canonical transcript exons
ENST00000529331 — 2 exons
| Exon | Start | End |
|---|---|---|
| ENSE00002166488 | 76381323 | 76382293 |
| ENSE00002182624 | 76403660 | 76408132 |
Expression profiles
Bgee: expression breadth ubiquitous, 187 present calls, max score 79.04.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.0027 / max 107.3570, expressed in 1261 samples.
FANTOM5 promoters (2 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 115938 | 4.8651 | 1253 |
| 115939 | 0.1376 | 63 |
Top tissues by expression
242 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| cortical plate | UBERON:0005343 | 79.04 | gold quality |
| body of pancreas | UBERON:0001150 | 77.49 | gold quality |
| buccal mucosa cell | CL:0002336 | 77.16 | silver quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 77.00 | gold quality |
| cerebellar hemisphere | UBERON:0002245 | 76.92 | gold quality |
| cerebellar cortex | UBERON:0002129 | 76.91 | gold quality |
| cerebellum | UBERON:0002037 | 76.64 | gold quality |
| right hemisphere of cerebellum | UBERON:0014890 | 76.46 | gold quality |
| ganglionic eminence | UBERON:0004023 | 76.40 | gold quality |
| right uterine tube | UBERON:0001302 | 75.48 | gold quality |
| ventricular zone | UBERON:0003053 | 75.04 | gold quality |
| epithelium of nasopharynx | UBERON:0001951 | 75.03 | gold quality |
| primary visual cortex | UBERON:0002436 | 75.03 | gold quality |
| Brodmann (1909) area 23 | UBERON:0013554 | 74.54 | gold quality |
| middle temporal gyrus | UBERON:0002771 | 74.21 | gold quality |
| calcaneal tendon | UBERON:0003701 | 74.07 | gold quality |
| prefrontal cortex | UBERON:0000451 | 73.76 | gold quality |
| pancreas | UBERON:0001264 | 73.62 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 73.13 | gold quality |
| adrenal tissue | UBERON:0018303 | 72.99 | gold quality |
| cerebellar vermis | UBERON:0004720 | 72.86 | silver quality |
| occipital lobe | UBERON:0002021 | 71.85 | gold quality |
| neocortex | UBERON:0001950 | 71.83 | gold quality |
| dorsolateral prefrontal cortex | UBERON:0009834 | 71.82 | gold quality |
| frontal cortex | UBERON:0001870 | 71.79 | gold quality |
| mucosa of paranasal sinus | UBERON:0005030 | 71.76 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 71.73 | gold quality |
| right frontal lobe | UBERON:0002810 | 71.16 | gold quality |
| cerebral cortex | UBERON:0000956 | 71.01 | gold quality |
| corpus callosum | UBERON:0002336 | 70.69 | gold quality |
Single-cell (SCXA)
Detected in 5 experiment(s), a significant marker in 2.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-MTAB-7249 | yes | 19.75 |
| E-ANND-3 | yes | 6.33 |
| E-MTAB-7606 | no | 16.40 |
| E-GEOD-81547 | no | 4.58 |
| E-MTAB-5061 | no | 2.05 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
134 targeting GVQW3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-190A-3P | 100.00 | 80.35 | 5520 |
| HSA-MIR-5011-5P | 100.00 | 83.46 | 5820 |
| HSA-MIR-450A-1-3P | 100.00 | 69.33 | 1837 |
| HSA-MIR-6740-5P | 100.00 | 65.64 | 932 |
| HSA-MIR-4533 | 100.00 | 69.48 | 2758 |
| HSA-MIR-3163 | 100.00 | 77.23 | 8605 |
| HSA-MIR-3613-3P | 100.00 | 76.36 | 7965 |
| HSA-MIR-371B-5P | 99.99 | 75.34 | 4759 |
| HSA-MIR-373-5P | 99.98 | 75.36 | 4753 |
| HSA-MIR-616-5P | 99.98 | 75.58 | 4775 |
| HSA-MIR-4775 | 99.98 | 75.00 | 6394 |
| HSA-MIR-548N | 99.98 | 71.94 | 4170 |
| HSA-MIR-12136 | 99.98 | 72.81 | 5713 |
| HSA-MIR-7152-3P | 99.97 | 67.47 | 849 |
| HSA-MIR-590-3P | 99.96 | 74.34 | 6478 |
| HSA-MIR-6778-3P | 99.96 | 67.29 | 2693 |
| HSA-MIR-548AB | 99.95 | 71.31 | 3488 |
| HSA-MIR-559 | 99.95 | 72.28 | 3609 |
| HSA-MIR-3912-5P | 99.95 | 66.11 | 925 |
| HSA-MIR-548A-5P | 99.94 | 71.27 | 3482 |
| HSA-MIR-548AD-5P | 99.94 | 71.23 | 3502 |
| HSA-MIR-548AE-5P | 99.94 | 71.23 | 3502 |
| HSA-MIR-548AK | 99.94 | 71.24 | 3488 |
| HSA-MIR-548AM-5P | 99.94 | 71.24 | 3488 |
| HSA-MIR-548AP-5P | 99.94 | 71.14 | 3489 |
| HSA-MIR-548AR-5P | 99.94 | 71.28 | 3515 |
| HSA-MIR-548AS-5P | 99.94 | 71.22 | 3482 |
| HSA-MIR-548AU-5P | 99.94 | 71.24 | 3488 |
| HSA-MIR-548AY-5P | 99.94 | 71.23 | 3502 |
| HSA-MIR-548B-5P | 99.94 | 71.23 | 3502 |
Cross-species orthologs
0 orthologs
Paralogs (1): SETMAR (ENSG00000170364)
Protein
Protein identifiers
Protein GVQW3 — Q3ZCU0 (reviewed: Q3ZCU0)
Alternative names: GVQW motif-containing protein 3
All UniProt accessions (5): A0A0U1RQW1, A0A590UK82, A0A590UKB8, A0A669KB94, Q3ZCU0
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q3ZCU0-1 | 1 | yes |
| Q3ZCU0-2 | 2 |
RefSeq proteins (4): NP_001269385, NP_001292154, NP_001334813, NP_001334814* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR041426 | Mos1_HTH | Domain |
| IPR052709 | Transposase-MT_Hybrid | Family |
Pfam: PF17906
UniProt features (3 total): splice variant 2, chain 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q3ZCU0-F1 | 61.24 | 0.19 |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 40 (showing top):
chr11q13, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, ZWANG_DOWN_BY_2ND_EGF_PULSE, SRC_UP.V1_UP, ARID5B_TARGET_GENES, E2F5_TARGET_GENES, HOXB6_TARGET_GENES, ID1_TARGET_GENES, NAB2_TARGET_GENES, SFMBT1_TARGET_GENES, ZNF513_TARGET_GENES, ZNF618_TARGET_GENES, ZNF7_TARGET_GENES, ZNF711_TARGET_GENES, ZNF768_TARGET_GENES
GO Biological Process (0):
GO Molecular Function (0):
GO Cellular Component (0):
Protein interactions and networks
STRING
779 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| GVQW3 | ELOC | Q15369 | 213 |
| GVQW3 | DICER1 | Q9UPY3 | 204 |
| GVQW3 | SPO11 | Q9Y5K1 | 166 |
| GVQW3 | UBXN7 | O94888 | 164 |
| GVQW3 | DDB1 | Q16531 | 162 |
| GVQW3 | BCHE | P06276 | 159 |
| GVQW3 | ACHE | P22303 | 159 |
| GVQW3 | PHYH | O14832 | 158 |
| GVQW3 | PHYHD1 | Q5SRE7 | 158 |
| GVQW3 | METAP1 | P53582 | 157 |
| GVQW3 | GLA | P06280 | 156 |
| GVQW3 | EDF1 | O60869 | 156 |
| GVQW3 | NAGA | P17050 | 156 |
| GVQW3 | LIPT2 | A6NK58 | 155 |
| GVQW3 | KCNE3 | Q9Y6H6 | 155 |
IntAct
0 interactions, top by confidence:
BioGRID (3): LOC100506127 (Affinity Capture-MS), LOC100506127 (Affinity Capture-MS), LOC100506127 (Cross-Linking-MS (XL-MS))
ESM2 similar proteins: C0H3V9, L0TGF0, O05023, O28512, O29191, O59008, P03850, P0CF86, P0CF87, P11257, P16530, P19680, P21084, P23081, P25908, P26947, P37133, P39351, P43942, P44151, P44218, P49261, P50581, P55457, P55461, P71339, P75679, P92516, P9WF98, P9WF99, Q04616, Q04977, Q06517, Q06715, Q2EER5, Q2XXR3, Q3ZCU0, Q44233, Q44930, Q47718
Diamond homologs: O00592, Q04864, Q3ZCU0, Q6UX73, Q6ZUF6, Q7JQ07, Q8N769, Q9H2J1, A0A096LPI5, A7MCS3, Q3UST5, Q6B4Z3, Q86U02, Q8IUI4, Q8N7M2, Q8NDZ0, Q53H47, O14628, O94966, Q5VW38, Q96ET8, Q9NV72, Q9Y2Z0, Q5SR53
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
1 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 0 |
| Likely benign | 1 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
724 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 11:76382086:G:GT | donor_gain | 0.9700 |
| 11:76382173:G:GT | donor_gain | 0.9700 |
| 11:76382833:G:T | donor_gain | 0.9600 |
| 11:76403878:G:GT | donor_gain | 0.9600 |
| 11:76382066:G:GT | donor_gain | 0.9100 |
| 11:76382101:G:T | donor_gain | 0.9100 |
| 11:76382258:GAAAC:G | donor_gain | 0.9100 |
| 11:76382209:GG:G | donor_gain | 0.8900 |
| 11:76382210:GG:G | donor_gain | 0.8900 |
| 11:76382061:TC:T | donor_gain | 0.8800 |
| 11:76382833:G:GT | donor_gain | 0.8800 |
| 11:76382259:A:T | donor_gain | 0.8700 |
| 11:76382434:AGCTG:A | donor_gain | 0.8700 |
| 11:76382062:C:A | donor_gain | 0.8600 |
| 11:76382433:T:TA | donor_gain | 0.8600 |
| 11:76382074:T:A | donor_gain | 0.8400 |
| 11:76381976:TTTA:T | donor_gain | 0.8300 |
| 11:76382436:C:G | donor_gain | 0.8300 |
| 11:76381855:GA:G | donor_gain | 0.8200 |
| 11:76382117:T:G | donor_gain | 0.8200 |
| 11:76382087:C:T | donor_gain | 0.8100 |
| 11:76382897:GGCC:G | donor_gain | 0.8100 |
| 11:76382920:T:TA | donor_gain | 0.8100 |
| 11:76382921:A:AA | donor_gain | 0.8100 |
| 11:76395120:A:AG | donor_gain | 0.8100 |
| 11:76395121:T:G | donor_gain | 0.8100 |
| 11:76382101:G:GT | donor_gain | 0.8000 |
| 11:76385725:T:TA | donor_gain | 0.8000 |
| 11:76400209:TTC:T | donor_gain | 0.8000 |
| 11:76382100:GGA:G | donor_gain | 0.7900 |
AlphaMissense
1224 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 11:76381958:T:C | F44L | 0.999 |
| 11:76381960:T:A | F44L | 0.999 |
| 11:76381960:T:G | F44L | 0.999 |
| 11:76381976:T:C | F50L | 0.999 |
| 11:76381978:T:A | F50L | 0.999 |
| 11:76381978:T:G | F50L | 0.999 |
| 11:76381855:G:C | R9S | 0.998 |
| 11:76381855:G:T | R9S | 0.998 |
| 11:76381868:T:C | F14L | 0.998 |
| 11:76381870:T:A | F14L | 0.998 |
| 11:76381870:T:G | F14L | 0.998 |
| 11:76381914:T:C | L29S | 0.998 |
| 11:76381964:T:A | W46R | 0.998 |
| 11:76381964:T:C | W46R | 0.998 |
| 11:76381977:T:C | F50S | 0.998 |
| 11:76382108:G:C | A94P | 0.998 |
| 11:76382139:T:A | V104D | 0.998 |
| 11:76381854:G:C | R9T | 0.997 |
| 11:76381854:G:T | R9M | 0.997 |
| 11:76381911:T:C | L28P | 0.997 |
| 11:76381966:G:C | W46C | 0.997 |
| 11:76381966:G:T | W46C | 0.997 |
| 11:76381852:A:C | Q8H | 0.996 |
| 11:76381852:A:T | Q8H | 0.996 |
| 11:76381859:A:C | S11R | 0.996 |
| 11:76381861:T:A | S11R | 0.996 |
| 11:76381861:T:G | S11R | 0.996 |
| 11:76381956:T:A | V43D | 0.996 |
| 11:76381965:G:C | W46S | 0.996 |
| 11:76381967:C:G | H47D | 0.996 |
dbSNP variants (sampled 300 via entrez): RS1000136620 (11:76380004 T>C), RS1000175259 (11:76384483 C>A,T), RS1000203085 (11:76384189 T>C), RS1000218844 (11:76411190 G>A), RS1000229417 (11:76399929 T>G), RS1000341859 (11:76400187 A>C), RS1000402271 (11:76379750 G>A), RS1000594405 (11:76408747 C>T), RS1000755606 (11:76402295 G>A), RS1000807428 (11:76395679 A>C), RS1000818162 (11:76392752 G>A,C), RS1000825283 (11:76412796 G>A,C), RS1001009047 (11:76381104 G>C), RS1001177565 (11:76382926 C>T), RS1001180387 (11:76407519 G>A)
Disease associations
OMIM: gene `` | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
3 total (human), top 3 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| triphenyl phosphate | affects expression | 1 |
| abrine | decreases expression | 1 |
| Tobacco Smoke Pollution | decreases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.